An Introduction to Medicinal Chemistry

More documents

Recommendations

Info

104 Drug development O IIS—NH — C—NH-CH2CH 2CH 2CH 3 O O Fig. 7.29 Cimetidine. Fig. 7.30 Tolbutamide. described above. Clearly, this is a more demanding objective, but the cimetidine s<strong>to</strong>ry proves that
A case study—oxamniquine
Page 1 and 2:
An Introduction to Medicinal Chemis
Page 3 and 4:
Preface This text is aimed at under
Page 5 and 6:
Contents Classification of drugs xi
Page 7 and 8:
Contents
Page 9 and 10:
Contents xi 11.16.2 Structure
Page 11 and 12:
Classification of drugs
Page 13 and 14:
1 • Drugs and the medicinal chemi
Page 15 and 16:
Whilst penicillin Drugs and the med
Page 17:
Drugs
Page 22 and 23:
10 The why and the wherefore Cytopl
Page 25:
Where do drugs work? 13 Amphoterici
Page 28:
16 Protein structure [ H O
Page 31 and 32:
The tertiary structure of proteins
Page 33 and 34:
The tertiary structure of proteins
Page 36 and 37:
24 Protein structure H-Bond Peptide
Page 38:
26 Protein structure again that ter
Page 43 and 44:
Substrate binding
Page 45 and 46:
Substrate binding at an active site
Page 47:
Substrate binding
Page 53 and 54:
R The catalytic role of enzymes Thy
Page 55 and 56:
I NH 2 CHO (OH Condensation R< The
Page 59 and 60:
Nerve Neurotransmitters
Page 61 and 62:
Receptors
Page 64 and 65:
52 Drug action at receptors Induced
Page 66 and 67: 54 Drug action at receptors MESSENG
Page 68: 56 Drug action at receptors RECEPTO
Page 72 and 73: 60 Drug action at receptors left-ha
Page 74 and 75: 62 Drug action
Page 76 and 77: 64 Drug action
Page 78 and 79: 66 Drug action at receptors D Neuro
Page 81 and 82: Structure of DNA 69 NH 2 NHo NHo Ad
Page 83 and 84: Structure
Page 85 and 86: Drugs acting
Page 87: Drugs acting on DNA 75 CH3—N: MEC
Page 90 and 91: 78 Nucleic acids end AMINO «A/* Ba
Page 93: Summary 81
Page 96 and 97: 84 Drug development
Page 98 and 99: 86 Drug development | | Potential I
Page 100 and 101: 88 Drug development bonding or not,
Page 102 and 103: 90 Drug development 7.5.1 Variation
Page 104 and 105: 92 Drug development covered
Page 106 and 107: 94 Drug development avoiding patent
Page 108 and 109: 96 Drug development ,OH OH GLIPINE
Page 111: Receptor theories
Page 115: Lead compounds
Page 119 and 120: A case study—oxamniquine
Page 121 and 122: A case study—oxamniquine 109 CH 3
Page 124 and 125: 112 Pharmacodynamics stream. Thirdl
Page 127 and 128: Drug dose levels 115 can easily neg
Page 129 and 130: Drug design for pharmacokinetic pro
Page 131 and 132: Drug design
Page 139: grown Neurotransmitters as drugs? 1
Page 142 and 143: 130 Quantitative structure-activity
Page 164: 152 Quantitative structure-activity
Page 170 and 171:
158 Antibacterial agents
Page 173 and 174:
others. Antibacterial agents which
Page 175 and 176:
Antibacterial agents which act agai
Page 177 and 178:
Antibacterial agents which
Page 179 and 180:
Antibacterial agents which inhibit
Page 181 and 182:
Page 183:
is tolerated Antibacterial agents w
Page 186 and 187:
174 Antibacterial agents The proble
Page 188 and 189:
176 Antibacterial agents Permeabili
Page 190 and 191:
178 Antibacterial agents H0 2C—C
Page 192 and 193:
180 R
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Antibacterial agents which impair p
Page 213 and 214:
Agents which
Page 215 and 216:
Drug resistance 203 10.9 Drug resis
Page 217 and 218:
11- The peripheral nervous system
Page 219 and 220:
Motor nerves
Page 221 and 222:
Actions
Page 223 and 224:
The cholinergic system 211 I j V Ac
Page 225:
Agonists
Page 229:
Agonists at the cholinergic recepto
Page 232 and 233:
220 The peripheral nervous system
Page 235 and 236:
Antagonists
Page 237:
Structural analogues based Antagoni
Page 240 and 241:
228 The peripheral nervous system I
Page 242 and 243:
230 The peripheral nervous system p
Page 244 and 245:
232 The peripheral nervous system ;
Page 247:
Anticholinesterases
Page 250 and 251:
238 The peripheral nervous system r
Page 253 and 254:
Anticholinesterase drugs
Page 255 and 256:
Anticholinesterase drugs
Page 257:
Pralidoxime—an organophosphate an
Page 260 and 261:
248 The opium analgesics Chinese de
Page 263:
Morphine
Page 267:
Development of morphine analogues 2
Page 270 and 271:
258 The opium analgesics R= ——C
Page 272 and 273:
260 The opium analgesics (A) BINDIN
Page 274 and 275:
262 The opium analgesics morphine.
Page 276 and 277:
264 The opium analgesics o N——C
Page 278 and 279:
266 The opium analgesics morphine
Page 281 and 282:
Receptor theory
Page 283 and 284:
Receptor theory
Page 285:
Agonists
Page 289 and 290:
e Receptor mechanisms 277
Page 291 and 292:
membrane to a second membrane-bound
Page 296 and 297:
284 Cimetidine—a rational approac
Page 299:
Searching
Page 302 and 303:
Page 305:
From partial agonist
Page 309:
Development of metiamide 297 the sa
Page 313:
Cimetidine
Page 316 and 317:
304 Cimetidine — a rational appro
Page 318 and 319:
Page 320 and 321:
Page 324 and 325:
Page 326 and 327:
Appendix
Page 329:
a The action of nerves 317
Page 332 and 333:
Appendix
Page 334 and 335:
322 Secondary messengers number
Page 337 and 338:
Secondary messengers
Page 339 and 340:
Haemophilus influenzae Bacteroides
Page 341 and 342:
Glossary
Page 343:
Index acetylcholine 47-8, 207, 209-
Page 346 and 347:
334 Index intestinal infections
Page 348:
336 Index structure-activity analys
show all

An Introduction to Medicinal Chemistry

Create successful ePaper yourself

Delete template?

Save as template?